Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients

Phase 3

Completed

Conditions: Age Related Macular Degeneration

Interventions: Drug: ranibizumab 0.5 mg

First Posted Date: 2009-01-22

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 114

Registration Number: NCT00826371

Locations: 🇨🇳
Novartis Investigational Site, Chengdu, China
🇨🇳
Novartis Investigative Site, Shanghai, China

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: AQW051

First Posted Date: 2009-01-21

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT00825539

Locations: 🇺🇸
Massachusetts General Hospital (Freedom Trail Clinic), Boston, Massachusetts, United States
🇺🇸
Maryland Psychiatric Research Centre, Spring Grove Hospital Grounds, Baltimore, Maryland, United States
🇺🇸
Department of Psychiatry & Behavioural Sciences, Feinberg School of Medicine (Northwestern University), Chicago, Illinois, United States

and more 4 locations

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukaemia, Lymphocytic, Chronic

Interventions: Drug: FC infusion
Drug: OFC Infusion

First Posted Date: 2009-01-16

Last Posted Date: 2020-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 365

Registration Number: NCT00824265

Locations: 🇬🇧
Novartis Investigative Site, Uxbridge, United Kingdom
🇧🇷
Novartis Investigation Site, Rio de Janeiro, Brazil
🇺🇦
Novartis Investigational Site, Zhytomyr, Ukraine

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol 150 µg
Drug: Salmeterol 50 µg
Drug: Placebo to salmeterol
Drug: Placebo to indacaterol

First Posted Date: 2009-01-13

Last Posted Date: 2011-08-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1123

Registration Number: NCT00821093

Locations: 🇺🇸
Novartis Investigative Center, Clearwater, Florida, United States
🇺🇸
Novartis Investigative site, Spartanburg, South Carolina, United States
🇩🇪
Novartis Investgative Site, Witten, Germany

and more 3 locations

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastases, Brain

Interventions: Drug: capecitabine
Drug: lapatinib
Drug: trastuzumab

First Posted Date: 2009-01-12

Last Posted Date: 2019-04-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 540

Registration Number: NCT00820222

Locations: 🇬🇧
Novartis Investigative Site, Worthing, United Kingdom

Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplantation

Interventions: Drug: AEB071 200 mg b.i.d. / everolimus
Drug: cyclosporine (reduced exposure) / everolimus
Drug: AEB071 300 mg b.i.d. / everolimus

First Posted Date: 2009-01-12

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT00820911

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Phase 2

Completed

Conditions: Gout

Interventions: Drug: Canakinumab
Drug: Allopurinol
Drug: Colchicine
Drug: Placebo Matching Canakinumab
Drug: Placebo Matching Colchicine

First Posted Date: 2009-01-09

Last Posted Date: 2018-07-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 432

Registration Number: NCT00819585

Locations: 🇺🇸
Talbert Medical Group, Huntington Beach, California, United States
🇺🇸
Health Awareness, Jupiter, Florida, United States
🇺🇸
East-West Medical Research institute, Honolulu, Hawaii, United States

and more 28 locations

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Phase 1

Completed

Conditions: Renal Impairment
Diabetes

Interventions: Drug: Vildagliptin

First Posted Date: 2009-01-07

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT00818571

Locations: 🇷🇺
Novartis Investigator Site, Moscow, Russian Federation

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

Phase 2

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: AIN457
Drug: Placebo

First Posted Date: 2008-12-17

Last Posted Date: 2015-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00809159

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: Placebo
Biological: AIN457

First Posted Date: 2008-12-17

Last Posted Date: 2015-11-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT00809614

Locations: 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy